CGT Catapult Modern Slavery Statement

OUR COMMITMENT TO THE PRINCIPLES OF THE MODERN SLAVERY ACT 2015

Cell and Gene Therapy Catapult is committed to the principles of the Modern Slavery Act 2015 and the abolition of modern slavery and human trafficking. It has a zero-tolerance policy towards any activities which support slavery and/or human trafficking in its own business and supply chain.

OUR PEOPLE

As a responsible employer, we are committed to creating and ensuring a non-discriminatory and respectful working environment for our employees. We want all our employees to feel confident that they can expose wrongdoing without any risk to themselves.

Our recruitment and people management processes are designed to ensure that all prospective employees are legally entitled to work in the UK and to safeguard employees from any abuse or coercion. We recognise and adhere to the principles of the UK Universities Concordat for Research Integrity.

OUR SUPPLY CHAIN

Due to the nature of our business, delivering life changing advanced therapies to patients by creating unique collaborations to develop new technology and innovation, we are at low risk of modern slavery in our business and supply chain. Our supply chain is limited, and we procure goods and services from a restricted range of UK and overseas suppliers. We expect our collaborators and suppliers to uphold similar values and ensure we have appropriate contractual procedures in place with all people and organisations we work with.

OUR POLICIES IN RELATION TO THE MODERN SLAVERY ACT 2015

CGT Catapult ensure compliance with this statement though the following Policies and Procedures which all staff have free access to :

  • Equal Opportunities Policy relating to Disability
  • Equal Opportunities Policy
  • Whistleblowing Policy
  • Anti-Harassment and Bullying Policy
  • Recruitment Policy
  • Engagement with Goods and Services Providers
  • Procedure for the Assessment of Suppliers Providing Personal Data Services

This statement has been approved for the financial year ending 31 March 2022. This statement will be reviewed annually by the Human Resources department and updated accordingly.

This statement was approved by a sub-committee of the Board on 12 August 2021.

  • Do you want to work for the Cell and Gene Therapy Catapult? We have a whole range of exciting new opportunities🧬🔬… https://t.co/Q5JSlZ4BkO 2 days 4 hours ago

Discover who we are